Sakai Clinic 62 Founder & Medical Director Mari Sakai Holds Dialogue with Peter Nobel, Chairman of the Nobel Sustainability Trust, Declaring Global Leadership as a Pioneer of Medical Sustainability
TOKYO, Jan. 20, 2026 /PRNewswire/ -- Sakai Clinic 62 (Location: Shibuya-ku, Tokyo; Founder & Medical Director: Mari Sakai) announces that Dr. Mari Sakai held a dialogue with Mr. Peter Nobel, Chairman of the Nobel Sustainability Trust (NST), to discuss the international promotion of sustainability within the medical field. Peter Nobel and Mari Sakai ...
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene’s NouvNeu001, Making It the World’s First iPSC Therapy with Both FTD and RMAT Recognitions
Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data CHENGDU, China, Jan. 19, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, today announced that its lead product, NouvNeu001, has been granted Regenerative Medicine...
Ageing, smoking, oral bacteria and genetic mutations linked to higher stomach cancer risk
Duke-NUS and NUHS scientists uncover a complex web of genetic, age-related and microbial factors that increase the risk of stomach cancer. Age-related blood cell mutations may trigger early changes in the stomach lining, offering new insights into how cancer risk builds over time and underscoring the importance of healthy ageing. Findings point to new ways to identify individuals at...
Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis
HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). There are approximately 4 million AS...
6Letters Launches “MOJO KING,” an Apple Watch-Based iOS App for Non-Invasive Testosterone Monitoring
SEOUL, South Korea, Jan. 19, 2026 /PRNewswire/ -- Digital healthcare startup 6Letters today announced the official launch of MOJO KING, an iOS application that enables non-invasive monitoring of testosterone-related physiological patterns using Apple Watch data. 6Letters Launches “MOJO KING,” an Apple Watch–Based iOS App for Non-Invasive Testosterone Monitoring MOJO KING leverages heart rate variability...
Smartee Denti-Technology Releases 2025 Year-in-Review: 100,000 GS Mandibular Repositioning Cases, Global Expansion, and Manufacturing Scale-Up
SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- Smartee Denti-Technology today released its 2025 annual review, detailing a pivotal year characterized by the worldwide clinical application of its proprietary mandibular repositioning technology, the inauguration of new European infrastructure, and a strategic partnership with the Straumann Group. The 2025 review highlights Smartee's transition from rapid growth to sustained maturity, underscored by advancements in...
Sharjah Achieves Historic WHO Age-Friendly Status
SHARJAH, UAE, Jan. 19, 2026 /PRNewswire/ -- The Emirate of Sharjah, UAE, has reached a new global milestone by obtaining "Advanced Affiliate" membership in the World Health Organization's (WHO) Global Network for Age-Friendly Cities and Communities. This makes Sharjah the first Arab city to achieve this prestigious status. This achievement underscores the emirate's deep commitment to enhancing the well-being...
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications: D3S‑003 — a KRAS G12D inhibitor — enabling the start of a Phase 1 first‑in‑human...
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq:...
A Smarter New Year’s Resolution: Investing in Eye Comfort for Screen Heavy Workdays
SYDNEY, Jan. 19, 2026 /PRNewswire/ -- As the new year begins, many Australians are setting resolutions focused on health, balance and long-term wellbeing. While fitness goals and productivity upgrades often dominate the conversation, eye comfort during extended screen use is frequently overlooked. With work, communication and entertainment increasingly centred around screens, visual fatigue has become a common challenge, particularly...
